| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
|
J Clin Oncol
|
2002
|
4.69
|
|
2
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
4.64
|
|
3
|
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
Lancet Oncol
|
2012
|
4.19
|
|
4
|
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
|
J Clin Oncol
|
2012
|
3.92
|
|
5
|
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
|
Lancet Oncol
|
2012
|
2.86
|
|
6
|
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
|
J Clin Oncol
|
2007
|
2.80
|
|
7
|
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
|
J Clin Oncol
|
2010
|
2.43
|
|
8
|
A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release.
|
Drug Alcohol Depend
|
2007
|
2.22
|
|
9
|
A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression.
|
J Am Acad Child Adolesc Psychiatry
|
2006
|
2.20
|
|
10
|
A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease.
|
J Subst Abuse Treat
|
2009
|
2.03
|
|
11
|
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
|
J Clin Oncol
|
2005
|
1.99
|
|
12
|
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
|
Clin Cancer Res
|
2012
|
1.64
|
|
13
|
A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes.
|
Crim Justice Behav
|
2008
|
1.54
|
|
14
|
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
|
J Clin Oncol
|
2003
|
1.49
|
|
15
|
Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico.
|
J Addict Med
|
2007
|
1.47
|
|
16
|
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
|
Clin Cancer Res
|
2010
|
1.34
|
|
17
|
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
|
Gynecol Oncol
|
2012
|
1.31
|
|
18
|
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
|
Cancer
|
2010
|
1.24
|
|
19
|
Alpha-v integrins as therapeutic targets in oncology.
|
Cancer Invest
|
2007
|
1.22
|
|
20
|
Factors that predict adolescent motivation for substance abuse treatment.
|
J Subst Abuse Treat
|
2003
|
1.13
|
|
21
|
Interim methadone treatment: impact on arrests.
|
Drug Alcohol Depend
|
2009
|
1.09
|
|
22
|
Developing and Implementing a New Prison-Based Buprenorphine Treatment Program.
|
J Offender Rehabil
|
2010
|
1.07
|
|
23
|
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
|
Kidney Int
|
2003
|
1.06
|
|
24
|
Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime.
|
Subst Abus
|
2012
|
1.03
|
|
25
|
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.
|
Blood
|
2002
|
1.02
|
|
26
|
Innovations and challenges in renal cancer: consensus statement from the first international conference.
|
Clin Cancer Res
|
2004
|
1.02
|
|
27
|
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
|
Clin Cancer Res
|
2010
|
0.99
|
|
28
|
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
|
Subst Abus
|
2012
|
0.97
|
|
29
|
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
|
Clin Adv Hematol Oncol
|
2006
|
0.97
|
|
30
|
Evaluation of a group-based substance abuse treatment program for adolescents.
|
J Subst Abuse Treat
|
2004
|
0.96
|
|
31
|
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
|
Clin Cancer Res
|
2013
|
0.91
|
|
32
|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
|
Clin Cancer Res
|
2010
|
0.91
|
|
33
|
Endoglin for targeted cancer treatment.
|
Curr Oncol Rep
|
2014
|
0.89
|
|
34
|
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
|
J Transl Med
|
2012
|
0.87
|
|
35
|
Predicting retention of adolescents in substance abuse treatment.
|
Addict Behav
|
2004
|
0.86
|
|
36
|
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents.
|
Cancer Metastasis Rev
|
2006
|
0.84
|
|
37
|
Bedside cardiology skills training for the osteopathic internist using simulation technology.
|
J Am Osteopath Assoc
|
2003
|
0.84
|
|
38
|
Stroke training of prehospital providers: an example of simulation-enhanced blended learning and evaluation.
|
Med Teach
|
2005
|
0.83
|
|
39
|
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.81
|
|
40
|
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.
|
Clin Cancer Res
|
2011
|
0.80
|
|
41
|
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
|
J Clin Pharmacol
|
2014
|
0.80
|
|
42
|
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.
|
Future Oncol
|
2013
|
0.80
|
|
43
|
Skill improvement during emergency response to terrorism training.
|
Prehosp Emerg Care
|
2006
|
0.79
|
|
44
|
Postprison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners.
|
Am J Addict
|
2012
|
0.79
|
|
45
|
Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS.
|
Brain Stimul
|
2014
|
0.79
|
|
46
|
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors.
|
Invest New Drugs
|
2009
|
0.78
|
|
47
|
Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis.
|
Hematol Oncol Clin North Am
|
2004
|
0.78
|
|
48
|
Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies.
|
Am J Clin Oncol
|
2002
|
0.78
|
|
49
|
Development, implementation and outcomes of a training program for responders to acts of terrorism.
|
Prehosp Emerg Care
|
2006
|
0.78
|
|
50
|
Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.
|
J Pharm Sci
|
2013
|
0.78
|
|
51
|
Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes.
|
J Renin Angiotensin Aldosterone Syst
|
2006
|
0.78
|
|
52
|
Real-time template-assisted manipulation of nanoparticles in a multilayer nanofluidic chip.
|
Small
|
2011
|
0.77
|
|
53
|
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
|
Oncology
|
2002
|
0.77
|
|
54
|
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
|
Leuk Res
|
2006
|
0.77
|
|
55
|
Pretreatment illegal activities of a nationwide sample of adolescent substance abuse clients.
|
J Psychoactive Drugs
|
2004
|
0.76
|
|
56
|
The emerging role of darbepoetin alfa in the management of patients with cancer.
|
J Support Oncol
|
2005
|
0.75
|
|
57
|
Is bedside teaching necessary or acceptable in paediatrics?
|
Med J Aust
|
2013
|
0.75
|
|
58
|
Indirect interception actions by blind and sighted perceivers: the role of modality and tau.
|
Scand J Psychol
|
2011
|
0.75
|
|
59
|
What happens to depressed adolescents? A follow-up study into early adulthood.
|
J Affect Disord
|
2013
|
0.75
|
|
60
|
Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors.
|
Anticancer Drugs
|
2015
|
0.75
|
|
61
|
Indirect interception actions by blind and visually impaired perceivers: echolocation for interceptive actions.
|
Scand J Psychol
|
2009
|
0.75
|